Haemonetics (HAE) 10-Q 6 Nov 18 2019 Q2 Quarterly report Financial data

DOCUMENT AND ENTITY INFORMATION

DOCUMENT AND ENTITY INFORMATION - shares	6 Months Ended
	Sep. 29, 2018	Nov. 02, 2018
Document And Entity Information [Abstract]
Entity Registrant Name	HAEMONETICS CORP
Entity Central Index Key	313,143
Current Fiscal Year End Date	--03-30
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Sep. 29, 2018
Document Fiscal Year Focus	2,019
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Common Stock, Shares Outstanding		51,684,326

CONSOLIDATED STATEMENTS OF INCO

CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 29, 2018	Sep. 30, 2017	Sep. 29, 2018	Sep. 30, 2017
Income Statement [Abstract]
Net revenues	$ 241,581	$ 225,377	$ 470,928	$ 436,328
Cost of goods sold	129,674	120,815	275,777	240,101
Gross profit	111,907	104,562	195,151	196,227
Operating expenses:
Research and development	8,583	7,521	17,989	15,714
Selling, general and administrative	77,248	72,783	145,793	139,644
Total operating expenses	85,831	80,304	163,782	155,358
Operating income	26,076	24,258	31,369	40,869
Gain on divestiture	0	0	0	8,000
Interest and other expense, net	(3,039)	(1,397)	(5,017)	(2,756)
Income before provision for income taxes	23,037	22,861	26,352	46,113
Provision for income taxes	4,311	2,759	10,445	5,874
Net income	$ 18,726	$ 20,102	$ 15,907	$ 40,239
Net income per share - basic (in dollars per share)	$ 0.36	$ 0.38	$ 0.31	$ 0.77
Net income per share - diluted (in dollars per share)	$ 0.35	$ 0.38	$ 0.30	$ 0.76
Weighted average shares outstanding
Basic (in shares)	51,605	52,619	51,862	52,531
Diluted (in shares)	53,138	52,981	53,365	52,896
Comprehensive income	$ 18,403	$ 21,937	$ 10,865	$ 45,703

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 29, 2018	Mar. 31, 2018
Current assets:
Cash and cash equivalents	$ 199,763	$ 180,169
Accounts receivable, less allowance of $3,253 at September 29, 2018 and $2,111 at March 31, 2018	161,590	151,226
Inventories, net	163,584	160,799
Prepaid expenses and other current assets	27,868	28,983
Total current assets	552,805	521,177
Property, plant and equipment, net	344,560	332,156
Intangible assets, less accumulated amortization of $264,742 at September 29, 2018 and $249,278 at March 31, 2018	141,483	156,589
Goodwill	210,844	211,395
Deferred tax asset	3,765	3,961
Other long-term assets	12,254	12,061
Total assets	1,265,711	1,237,339
Current liabilities:
Notes payable and current maturities of long-term debt	12,664	194,259
Accounts payable	57,857	55,265
Accrued payroll and related costs	49,132	69,519
Other liabilities	69,514	65,660
Total current liabilities	189,167	384,703
Long-term debt, net of current maturities	330,988	59,423
Deferred tax liability	13,235	6,526
Other long-term liabilities	30,983	34,258
Total stockholders’ equity
Common stock, $0.01 par value; Authorized — 150,000,000 shares; Issued and outstanding — 51,624,719 shares at September 29, 2018 and 52,342,965 shares at March 31, 2018	516	523
Additional paid-in capital	530,480	503,955
Retained earnings	194,375	266,942
Accumulated other comprehensive loss	(24,033)	(18,991)
Total stockholders’ equity	701,338	752,429
Total liabilities and stockholders’ equity	$ 1,265,711	$ 1,237,339

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($) $ in Thousands	Sep. 29, 2018	Mar. 31, 2018
Statement of Financial Position [Abstract]
Accounts receivable, allowance	$ 3,253	$ 2,111
Intangible assets, amortization	$ 264,742	$ 249,278
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares issued (in shares)	51,624,719	52,342,965
Common stock, shares outstanding (in shares)	51,624,719	52,342,965

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Sep. 29, 2018	Sep. 30, 2017
Cash Flows from Operating Activities:
Net income	$ 15,907	$ 40,239
Non-cash items:
Depreciation and amortization	51,692	43,986
Impairment of assets	21,170	0
Stock-based compensation expense	7,961	4,199
Gain on divestiture	0	(8,000)
Provision for losses on accounts receivable and inventory	549	688
Other non-cash operating activities	1,277	312
Change in operating assets and liabilities:
Change in accounts receivable	(13,326)	10,739
Change in inventories	(3,912)	7,284
Change in prepaid income taxes	(349)	776
Change in other assets and other liabilities	4,095	3,920
Change in accounts payable and accrued expenses	(4,585)	(6,815)
Net cash provided by operating activities	80,479	97,328
Cash Flows from Investing Activities:
Capital expenditures	(76,002)	(29,125)
Proceeds from divestiture	0	9,000
Proceeds from sale of property, plant and equipment	656	1,346
Net cash used in investing activities	(75,346)	(18,779)
Cash Flows from Financing Activities:
Term loan borrowings	347,780	0
Term loan borrowings	(258,103)	(28,455)
Proceeds from employee stock purchase plan	1,780	1,622
Proceeds from exercise of stock options	7,127	10,120
Share repurchases	(80,000)	0
Other financing activities	0	417
Net cash provided by (used in) financing activities	18,584	(16,296)
Effect of exchange rates on cash and cash equivalents	(4,123)	1,805
Net Change in Cash and Cash Equivalents	19,594	64,058
Cash and Cash Equivalents at Beginning of Period	180,169	139,564
Cash and Cash Equivalents at End of Period	199,763	203,622
Supplemental Disclosures of Cash Flow Information:
Interest paid	5,833	3,768
Income taxes paid	5,053	5,449
Transfers from inventory to fixed assets for placement of Haemonetics equipment	$ 12,099	$ 3,965

BASIS OF PRESENTATION

BASIS OF PRESENTATION	6 Months Ended
	Sep. 29, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION Basis of Presentation The accompanying unaudited consolidated financial statements of Haemonetics Corporation ("Haemonetics" or the "Company") presented herein have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of the Company's management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. All intercompany transactions have been eliminated. Operating results for the six months ended September 29, 2018 are not necessarily indicative of the results that may be expected for the full fiscal year ending March 30, 2019 or any other interim period. The Company has assessed its ability to continue as a going concern. As of September 29, 2018 , the Company has concluded that substantial doubt about its ability to continue as a going concern does not exist. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes included in the annual report on Form 10-K for the fiscal year ended March 31, 2018 . The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The Company had no significant subsequent events.

RECENT ACCOUNTING PRONOUNCEMENT

RECENT ACCOUNTING PRONOUNCEMENTS	6 Months Ended
	Sep. 29, 2018
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	RECENT ACCOUNTING PRONOUNCEMENTS Standards Implemented Revenue from Contracts with Customers (Topic 606) In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Codification ("ASC") Update No. 2014-09, Revenue from Contracts with Customers (Topic 606) . ASC Update No. 2014-09 stipulates that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, an entity should apply the following steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. In March 2016, the FASB issued ASC Update No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net) . The purpose of ASC Update No. 2016-08 is to clarify the guidance on principal versus agent considerations. It includes indicators that help to determine whether an entity controls the specified good or service before it is transferred to the customer and to assist in determining when the entity satisfied the performance obligation and as such, whether to recognize a gross or a net amount of consideration in its consolidated statement of operations. In April 2016, the FASB issued ASC Update No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing . The guidance clarifies that entities are not required to assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract. ASC Update No. 2016-10 also addresses how to determine whether promised goods or services are separately identifiable and permits entities to make a policy election to treat shipping and handling costs as fulfillment activities. In addition, it clarifies key provisions in Topic 606 related to licensing. The Company adopted ASU 2014-09 on April 1, 2018 using the modified retrospective method. Under this method, entities recognize the cumulative effect of applying the new standard at the date of initial application with no restatement of comparative periods presented. The cumulative effect of applying the new standard resulted in an increase to opening retained earnings of $1.5 million upon adoption of Topic 606 in April 2018, primarily related to deferred revenue associated with software contracts. Software revenue accounted for approximately 7.9% and 8.0% of total revenue for the three and six months ended September 29, 2018 , respectively, and for approximately 8.5% and 8.4% of total revenue for the three and six months ended September 30, 2017 , respectively. The new standard has been applied only to those contracts that were not completed as of March 31, 2018. The impact of adopting ASU 2014-09 was not significant to individual financial statement line items in the consolidated balance sheet and consolidated statement of income and comprehensive income. Other Recent Accounting Pronouncements In October 2016, the FASB issued ASC Update No. 2016-16, Income Taxes (Topic 740). The guidance requires companies to recognize the income tax effects of intercompany sales and transfers of assets, other than inventory, in the income statement as income tax expense (or benefit) in the period in which the transfer occurs. The Company adopted ASC Update No. 2016-16 during the first quarter of fiscal 2019. The adoption of ASC Update No. 2016-16 did not have a material impact on the Company's consolidated financial statements. In August 2016, the FASB issued ASC Update No. 2016-15, Statement of Cash Flow (Topic 230). The guidance reduces diversity in how certain cash receipts and cash payments are presented and classified in the consolidated statements of cash flows. The Company adopted ASC Update No. 2016-15 during the first quarter of fiscal 2019. The adoption of ASC Update No. 2016-15 did not have a material impact on the Company's consolidated financial statements. In May 2017, the FASB issued ASC Update No. 2017-09, Compensation - Stock Compensation: Scope of Modification Accounting (Topic 718). The guidance clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. The Company adopted ASC Update No. 2017-09 during the first quarter of fiscal 2019. The adoption of ASC Update No. 2017-09 did not have a material impact on the Company's consolidated financial statements. In August 2017, the FASB issued ASC Update No. 2017-12, Derivatives and Hedging: Targeted Improvements to Accounting for Hedging Activities (Topic 815). The new guidance makes more financial and non-financial hedging strategies eligible for hedge accounting, amends the presentation and disclosure requirements for hedging activities and changes how companies assess hedge effectiveness. The Company early adopted ASC Update No. 2017-12 during the second quarter of fiscal 2019. The adoption of ASC Update No. 2017-12 did not have an impact on the Company's consolidated financial statements or the classification of its designated and non-designated hedge contracts.

RESTRUCTURING

RESTRUCTURING	6 Months Ended
	Sep. 29, 2018
Restructuring and Related Activities [Abstract]
RESTRUCTURING	RESTRUCTURING On an ongoing basis, the Company reviews the global economy, the healthcare industry, and the markets in which it competes to identify opportunities for efficiencies, enhance commercial capabilities, align its resources and offer its customers better solutions. In order to realize these opportunities, the Company undertakes restructuring-type activities to transform its business. During fiscal 2018, the Company launched a Complexity Reduction Initiative (the "2018 Program"), a company-wide restructuring program designed to improve operational performance and reduce cost, freeing up resources to invest in accelerated growth. This program includes a reduction of headcount and operating costs which will enable a more streamlined organizational structure. The Company expects to incur aggregate charges between $50 million and $60 million associated with these actions, of which it expects $35 million to $40 million will consist of severance and other employee costs and the remainder will consist of other exit costs, primarily related to third party services. These charges, substantially all of which will result in cash outlays, will be incurred as the specific actions required to execute on these initiatives are identified and approved and are expected to continue through fiscal 2020. During the three and six months ended September 29, 2018 , the Company incurred $1.9 million and $5.3 million , respectively, of restructuring and turnaround costs under this program. Total cumulative charges under this program are $41.9 million . During fiscal 2017, the Company launched a restructuring program (the "2017 Program") designed to reposition its organization and improve its cost structure. During the three and six months ended September 29, 2018 , there were nominal restructuring and turnaround charges recorded under this program. During the three and six months ended September 30, 2017 , the Company incurred $5.2 million and $7.7 million , respectively, of restructuring and turnaround costs under this program. The 2017 Program is substantially complete. The following table summarizes the activity for restructuring reserves related to the 2018 Program and the 2017 Program for the six months ended September 29, 2018 , substantially all of which relates to employee severance and other employee costs: (In thousands) 2018 Program 2017 Program Total Balance at March 31, 2018 $ 27,129 $ 1,406 $ 28,535 Costs incurred, net of reversals (382 ) 57 (325 ) Payments (12,159 ) (984 ) (13,143 ) Non-cash adjustments (96 ) — (96 ) Balance at September 29, 2018 $ 14,492 $ 479 $ 14,971 The substantial majority of restructuring costs during the three and six months ended September 29, 2018 have been included as a component of selling, general and administrative expenses in the accompanying consolidated statements of income. As of September 29, 2018 , the Company had a restructuring liability of $15.0 million , of which $13.6 million is payable within the next twelve months. In addition to the restructuring costs included in the table above, during the three and six months ended September 29, 2018 , the Company also incurred costs of $2.2 million and $5.8 million , respectively, that do not constitute restructuring under ASC 420, Exit and Disposal Cost Obligations, which it refers to as turnaround costs. These costs, substantially all of which have been included as a component of selling, general and administrative expenses in the accompanying consolidated statements of income, consist primarily of expenditures directly related to the restructuring actions and include program management costs associated with the implementation of outsourcing initiatives and recent accounting standards. The tables below present restructuring and turnaround costs by reportable segment: Restructuring costs Three Months Ended Six Months Ended (In thousands) September 29, 2018 September 30, 2017 September 29, 2018 September 30, 2017 Japan $ 91 $ 2 $ 102 $ 111 EMEA (5 ) 15 119 25 North America Plasma — — (40 ) — All Other (119 ) 134 (506 ) 1,071 Total $ (33 ) $ 151 $ (325 ) $ 1,207 Turnaround costs Three Months Ended Six Months Ended (In thousands) September 29, 2018 September 30, 2017 September 29, 2018 September 30, 2017 Japan $ — $ — $ — $ — EMEA — 20 28 26 North America Plasma 31 197 41 349 All Other 2,120 5,419 5,723 6,688 Total $ 2,151 $ 5,636 $ 5,792 $ 7,063 Total restructuring and turnaround costs $ 2,118 $ 5,787 $ 5,467 $ 8,270

INCOME TAXES

INCOME TAXES	6 Months Ended
	Sep. 29, 2018
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The Company conducts business globally and reports its results of operations in a number of foreign jurisdictions in addition to the United States. The Company's reported tax rate is impacted by the jurisdictional mix of earnings in any given period as the foreign jurisdictions in which it operates have tax rates that differ from the U.S. statutory tax rate. The Company's reported tax rate for the three and six months ended September 29, 2018 was 18.7% and 39.6% , respectively. The rate for the three months ended September 29, 2018 includes a discrete stock compensation windfall benefit of $2.6 million . The rate for the six months ended September 29, 2018 is higher than the U.S. statutory tax rate primarily as a result of asset impairment expense of $21.2 million recorded in pretax income for which no tax benefit was recognized as a result of the valuation allowance maintained against its deferred tax assets in the impacted jurisdiction. Refer to Note 8, Property, Plant and Equipment for additional details . The Company's effective tax rate was also negatively impacted by certain provisions of the recently enacted U.S. tax reform as discussed below. During the three months ended September 29, 2018 and September 30, 2017 , the Company reported an income tax provision of $4.3 million and $2.8 million , respectively. During the six months ended September 29, 2018 and September 30, 2017 , the Company reported an income tax provision of $10.4 million and $5.9 million , respectively. The change in the Company's tax provision for both the three and six months ended September 29, 2018 was primarily due to an increase in the tax expense of its U.S. entity, which was impacted by the U.S. tax reform provisions discussed in more detail below, partially offset by a discrete stock compensation windfall benefit. During fiscal 2018, the Tax Cuts and Jobs Act (the "Act") was enacted in the United States. As of September 29, 2018 , the Company had not completed its accounting for the tax effects of the enactment of the Act. However, it has made a reasonable estimate of the effects on its existing deferred tax balances and the one-time transition tax. During the three and six months ended September 29, 2018 , the Company recognized an immaterial adjustment to the provisional tax expense estimate recorded related to the Act. The Company will continue to refine its calculations as additional analysis is completed. In addition, the Company's estimates may also be affected as it gains a more thorough understanding of the tax law. In the third quarter of fiscal 2019, the Company will finalize its accounting for the tax effects of the Act. The Company has incorporated the other impacts of the Act that became effective in fiscal 2019 in the calculation of the year to date tax provision and effective tax rate, including the provisions related to Global Intangible Low Taxed Income, Foreign Derived Intangible Income, Base Erosion Anti Abuse Tax, as well as other provisions which limit tax deductibility of expenses. The Company is in a three year cumulative loss position in the U.S. and, accordingly, maintains a valuation allowance against certain U.S. deferred tax assets. Additionally, the Company also maintains a valuation allowance against certain other deferred tax assets primarily in Switzerland, Puerto Rico, Luxembourg and France which it has concluded are not more-likely-than-not realizable.

EARNINGS PER SHARE ("EPS")

EARNINGS PER SHARE ("EPS")	6 Months Ended
	Sep. 29, 2018
Earnings Per Share [Abstract]
EARNINGS PER SHARE (EPS)	EARNINGS PER SHARE (“EPS”) The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations. Three Months Ended Six Months Ended (In thousands, except per share amounts) September 29, September 30, September 29, September 30, Basic EPS Net income $ 18,726 $ 20,102 $ 15,907 $ 40,239 Weighted average shares 51,605 52,619 51,862 52,531 Basic income per share $ 0.36 $ 0.38 $ 0.31 $ 0.77 Diluted EPS Net income $ 18,726 $ 20,102 $ 15,907 $ 40,239 Basic weighted average shares 51,605 52,619 51,862 52,531 Net effect of common stock equivalents 1,533 362 1,503 365 Diluted weighted average shares 53,138 52,981 53,365 52,896 Diluted income per share $ 0.35 $ 0.38 $ 0.30 $ 0.76 Basic earnings per share is calculated using the Company's weighted-average outstanding common stock. Diluted earnings per share is calculated using its weighted-average outstanding common stock including the dilutive effect of stock awards as determined under the treasury stock method. For the three and six months ended September 29, 2018 , weighted average shares outstanding, assuming dilution, excludes the impact of 0.2 million and 0.1 million anti-dilutive shares, respectively. For the three and six months ended September 30, 2017 , weighted average shares outstanding, assuming dilution, excludes the impact of 0.9 million and 0.8 million anti-dilutive shares, respectively. Share Repurchase Plan On February 6, 2018, the Company announced that its Board of Directors authorized the repurchase of up to $260 million of its outstanding common stock from time to time, based on market conditions, through March 30, 2019. In May 2018, the Company completed a $100.0 million repurchase of its common stock pursuant to an accelerated share repurchase agreement ("ASR") entered into with Citibank N.A (“Citibank”) in February 2018. The total number of shares repurchased under the ASR was approximately 1.4 million at an average price per share upon final settlement of $72.51 . In August 2018, the Company completed an additional $80.0 million repurchase of its common stock pursuant to an ASR entered into with Citibank in June 2018. The total number of shares repurchased under the ASR was approximately 0.9 million at an average price per share upon final settlement of $93.83 . As of September 29, 2018 , the total remaining authorization for repurchases of the Company’s common stock under its share repurchase program was $80.0 million .

REVENUE

REVENUE	6 Months Ended
	Sep. 29, 2018
Revenue from Contract with Customer [Abstract]
REVENUE	REVENUE The Company's revenue recognition policy is to recognize revenues from product sales, software and services in accordance with ASC Topic 606, Revenue from Contracts with Customers . Revenue is recognized when obligations under the terms of a contract with a customer are satisfied; this occurs with the transfer of control of the Company’s goods or services. The Company considers revenue to be earned when all of the following criteria are met: it has a contract with a customer that creates enforceable rights and obligations; promised products or services are identified; the transaction price, or the consideration it expects to receive for transferring goods or providing services, is determinable and it has transferred control of the promised items to the customer. A promise in a contract to transfer a distinct good or service to the customer is identified as a performance obligation. A contract’s transaction price is allocated to each performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Some of the Company’s contracts have multiple performance obligations. For contracts with multiple performance obligations, the Company allocates the contract’s transaction price to each performance obligation based on the estimated standalone selling prices of the good or service in the contract. For goods or services for which observable standalone selling prices are not available, the Company uses an expected cost plus a margin approach to estimate the standalone selling price of each performance obligation. As of September 29, 2018 , the Company had $26.2 million of its transaction price allocated to remaining performance obligations related to executed contracts with an original duration of one year or more. The Company expects to recognize approximately 57% of this amount as revenue within the next twelve months and the remaining balance thereafter. The Company adopted Topic 606 as of April 1, 2018, using the modified retrospective method. Under this method, entities recognize the cumulative effect of applying the new standard at the date of initial application with no restatement of comparative periods presented. The cumulative effect of applying the new standard resulted in an increase to opening retained earnings of $1.5 million upon adoption of Topic 606 on April 1, 2018, primarily related to deferred revenue associated with software revenue. The new standard has been applied only to those contracts that were not completed as of March 31, 2018. The impact of adopting Topic 606 was not significant to individual financial statement line items in the consolidated balance sheet as of September 29, 2018 or in the consolidated statements of income and comprehensive income for the three and six months ended September 29, 2018 . Product Revenues The majority of the Company’s performance obligations related to product sales are satisfied at a point in time. Product sales consist of the sale of its disposable blood component collection and processing sets and the related equipment. The Company’s performance obligation related to product sales is satisfied upon shipment or delivery to the customer based on the specified terms set forth in the customer contract. Shipping and handling activities performed after a customer obtains control of the good are treated as fulfillment activities and are not considered to be a separate performance obligation. Revenue is recognized over time for maintenance plans provided to customers that provide services beyond the Company’s standard warranty period. Payment terms between customers related to product sales vary by the type of customer, country of sale, and the products or services offered and could result in an unbilled receivable or deferred revenue balance depending on whether the performance obligation has been satisfied (or partially satisfied). For product sales to distributors, the Company recognizes revenue for both equipment and disposables upon shipment to distributors, which is when its performance obligations are complete. The Company's standard contracts with its distributors state that title to the equipment passes to the distributors at point of shipment to a distributor’s location. The distributors are responsible for shipment to the end customer along with any installation, training and acceptance of the equipment by the end customer. Payments from distributors are not contingent upon resale of the product. The Company also places equipment at customer sites. While the Company retains ownership of this equipment, the customer has the right to use it for a period of time provided they meet certain agreed to conditions. The Company recovers the cost of providing the equipment from the sale of its disposables. Software and Other Revenues To a lesser extent, the Company enters into other types of contracts including certain software licensing arrangements to provide software solutions to support its plasma, blood collection and hospital customers. A portion of its software sales are perpetual licenses typically accompanied by significant implementation services related to software customization as well as other professional and technical services. The Company generally recognizes revenue from the sale of perpetual licenses and related customization services over time (the Company is creating or enhancing an asset that the customer controls) using an input method which requires it to make estimates of the extent of progress toward completion of the contract. When the Company provides other services, including in some instances hosting, technical support and maintenance, it recognizes these fees and charges over time (the customer simultaneously receives and consumes benefits), as performance obligations for these services are satisfied during the contract period. Certain of its software licensing arrangements are term-based licenses that include a per-collection or a usage-based fee related to the use of the license and the related technical support and hosting services. For these usage-based arrangements, the Company applies the revenue recognition exception resulting in revenue recognition occurring upon the later of actual usage or satisfaction of the related performance obligations. The payment terms for software licensing arrangements vary by customer pursuant to the terms set forth in the customer contract and result in an unbilled receivable or deferred revenue balance depending on whether the performance obligation has been satisfied (or partially satisfied). Significant Judgments Revenues from product sales are recorded at the net sales price, which includes estimates of variable consideration related to rebates, product returns and volume discounts. These reserves are based on estimates of the amounts earned or to be claimed on the related sales. The Company's estimates take into consideration historical experience, current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the net sales price is limited to the amount that is probable not to result in a significant reversal in the amount of the cumulative revenue recognized in a future period. Revenue recognized in the current period related to performance obligations satisfied in prior periods was not material. Contract Balances The timing of revenue recognition, billings and cash collections result in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) on the consolidated balance sheets. The difference in timing between billing and revenue recognition primarily occurs in software licensing arrangements, resulting in contract assets and contract liabilities. As of September 29, 2018 and April 1, 2018, the Company had contract assets of $5.2 million and $2.7 million , respectively. The change is primarily due to the delay in billings compared to the revenue recognized. Contract assets are classified as other current assets and other long-term assets on the consolidated balance sheet. As of September 29, 2018 and April 1, 2018, the Company had contract liabilities of $16.4 million and $16.6 million , respectively. During the three and six months ended September 29, 2018 , the Company recognized $4.1 million and $11.5 million , respectively, of revenue that was included in the above April 1, 2018 contract liability balance. Contract liabilities are classified as other current liabilities and other long-term liabilities on the consolidated balance sheet. Practical Expedients The Company elected not to disclose the value of transaction price allocated to unsatisfied performance obligations for contracts with an original expected length of one year or less. When applicable, the Company has also elected to use the practical expedient to not adjust the promised amount of consideration for the effects of a significant financing component if it is expected, at contract inception, that the period between when the Company transfers a promised good or service to a customer, and when the customer pays for that good or service, will be one year or less.

INVENTORIES

INVENTORIES	6 Months Ended
	Sep. 29, 2018
Inventory Disclosure [Abstract]
INVENTORIES	INVENTORIES Inventories are stated at the lower of cost or market and include the cost of material, labor and manufacturing overhead. Cost is determined using the first-in, first-out method. (In thousands) September 29, March 31, 2018 (1) Raw materials $ 51,028 $ 52,997 Work-in-process 13,075 10,774 Finished goods 99,481 97,028 Total inventories $ 163,584 $ 160,799 (1) The Company corrected the classification of inventory as of March 31, 2018. This correction did not change total inventories and did not have a financial statement impact.

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	6 Months Ended
	Sep. 29, 2018
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	PROPERTY, PLANT AND EQUIPMENT As part of the acquisition of the whole blood business from Pall Corporation (“Pall”) in fiscal 2012, Pall agreed to manufacture and install in one of the Company's facilities a filter media manufacturing line (the “HDC line”) for which the Company agreed to pay Pall approximately $15.0 million (plus pre-approved overages). Pall also agreed to supply media to the Company for use in leukoreduction filters until such time as the Company accepted the HDC line. In May 2018, the Company entered into a long-term supply agreement with Pall under which Pall will continue to supply media to the Company for use in leukoreduction filters. As a condition of the supply agreement, the Company agreed to accept the HDC line and to make a final payment of $9.0 million to Pall for the HDC line. As a result of the decision to continue to source media for leukoreduction filters from Pall rather than producing them internally, the Company does not expect to utilize the HDC line for future production and expect that the asset’s future cash flows will not be sufficient to recover its carrying value of $19.8 million . Accordingly, during the first quarter of fiscal 2019 the Company recorded impairment charges of $19.8 million for the HDC line. During the first quarter of fiscal 2019, the Company also impaired $1.4 million of property, plant and equipment as a result of a review of non-core and underperforming assets and a decision to discontinue the use of or investment in certain assets. This impairment, as well as the impairment of the HDC line, were included within cost of goods sold on the consolidated statements of income and impacted the All Other reporting segment. Additionally, the Company has changed the estimated useful lives of PCS2 devices as these will be replaced by the NexSys PCS TM which the Company began placing during the second quarter of fiscal 2019. During the three and six months ended September 29, 2018 , the Company incurred $4.4 million and $8.4 million , respectively, of accelerated depreciation expense related to this change in estimate.

CAPITALIZATION OF SOFTWARE DEVE

CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS	6 Months Ended
	Sep. 29, 2018
Research and Development [Abstract]
CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS	CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS For costs incurred related to the development of software to be sold, leased or otherwise marketed, the Company applies the provisions of ASC 985-20, Software - Costs of Software to be Sold, Leased or Marketed , which specifies that costs incurred internally in researching and developing a computer software product should be charged to expense until technological feasibility has been established for the product. Once technological feasibility is established, all software costs should be capitalized until the product is available for general release to customers. The Company capitalized $1.5 million and $6.4 million of software development costs for ongoing initiatives during the six months ended September 29, 2018 and September 30, 2017 , respectively. At September 29, 2018 and March 31, 2018 , the Company had a total of $73.3 million and $71.8 million of capitalized software costs, respectively, of which $8.6 million and $17.7 million are related to in-process software development initiatives. During the six months ended September 29, 2018 , there were $10.6 million capitalized costs placed into service. The Company did not place any capitalized costs into service during the six months ended September 30, 2017 . The costs capitalized for each project are included in intangible assets in the consolidated financial statements.

PRODUCT WARRANTIES

PRODUCT WARRANTIES	6 Months Ended
	Sep. 29, 2018
Product Warranties Disclosures [Abstract]
PRODUCT WARRANTIES	PRODUCT WARRANTIES The Company generally provides warranty on parts and labor for one year after the sale and installation of each device. The Company also warrants disposables products through their use or expiration. The Company estimates its potential warranty expense based on its historical warranty experience and periodically assesses the adequacy of its warranty accrual, making adjustments as necessary. Six Months Ended (In thousands) September 29, September 30, Warranty accrual as of the beginning of the period $ 316 $ 176 Warranty provision 333 796 Warranty spending (392 ) (537 ) Warranty accrual as of the end of the period $ 257 $ 435

DEBT

DEBT	6 Months Ended
	Sep. 29, 2018
Debt Disclosure [Abstract]
NOTES PAYABLE AND LONG-TERM DEBT	NOTES PAYABLE AND LONG-TERM DEBT On June 15, 2018, the Company entered into a credit agreement with certain lenders which provided for a $350.0 million term loan (the "Term Loan") and a $350.0 million revolving loan (the "Revolving Credit Facility" and together with the Term Loan, the "Credit Facilities"). The Credit Facilities expire on June 15, 2023. Interest on the Credit Facilities is established using LIBOR plus 1.13% - 1.75% , depending on the Company's leverage ratio. Under the Credit Facilities, the Company is required to maintain certain leverage and interest coverage ratios specified in the credit agreement as well as other customary non-financial affirmative and negative covenants. A portion of the net proceeds of $347.8 million was used to pay down the $253.7 million remaining outstanding balance on the 2012 credit agreement, as amended in fiscal 2014. The remainder of the proceeds are available to be used to support the launch of the NexSys PCS device and for general corporate purposes. At September 29, 2018, $345.6 million was outstanding under the Term Loan with an effective interest rate of 3.5% and no amount was outstanding on the Revolving Credit Facility. The Company also has $24.5 million of uncommitted operating lines of credit to fund its global operations under which there were no outstanding borrowings as of September 29, 2018 . The Company has required scheduled principal payments of $8.8 million during fiscal 2019, $17.5 million during each fiscal 2020, fiscal 2021 and fiscal 2022, $214.4 million during fiscal 2023 and $70.0 million thereafter. The Company was in compliance with the leverage and interest coverage ratios specified in the Credit Facilities as well as all other bank covenants as of September 29, 2018 .

DERIVATIVES AND FAIR VALUE MEAS

DERIVATIVES AND FAIR VALUE MEASUREMENTS	6 Months Ended
	Sep. 29, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVES AND FAIR VALUE MEASUREMENTS	DERIVATIVES AND FAIR VALUE MEASUREMENTS The Company manufactures, markets and sells its products globally. During the three and six months ended September 29, 2018 , 36.7% and 37.3% , respectively, of its sales were generated outside the U.S., generally in foreign currencies. The Company also incurs certain manufacturing, marketing and selling costs in international markets in local currency. Accordingly, earnings and cash flows are exposed to market risk from changes in foreign currency exchange rates relative to the U.S. Dollar, the Company's reporting currency. The Company has a program in place that is designed to mitigate the exposure to changes in foreign currency exchange rates. That program includes the use of derivative financial instruments to minimize, for a period of time, the impact on its financial results from changes in foreign exchange rates. The Company utilizes foreign currency forward contracts to hedge the anticipated cash flows from transactions denominated in foreign currencies, primarily the Japanese Yen and the Euro, and to a lesser extent the Swiss Franc, Australian Dollar, Canadian Dollar and the Mexican Peso. This does not eliminate the impact of the volatility of foreign exchange rates. However, because the Company generally enters into forward contracts one year out, rates are fixed for a one -year period, thereby facilitating financial planning and resource allocation. Designated Foreign Currency Hedge Contracts All of the Company's designated foreign currency hedge contracts as of September 29, 2018 and March 31, 2018 were cash flow hedges under ASC 815, Derivatives and Hedging ("ASC 815"). The Company records the effective portion of any change in the fair value of designated foreign currency hedge contracts in other comprehensive income until the related third-party transaction occurs. Once the related third-party transaction occurs, the Company reclassifies the effective portion of any related gain or loss on the designated foreign currency hedge contracts to earnings. In the event the hedged forecasted transaction does not occur, or it becomes probable that it will not occur, the Company would reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time. The Company had designated foreign currency hedge contracts outstanding in the contract amount of $59.0 million as of September 29, 2018 and $86.0 million as of March 31, 2018 . At September 29, 2018 , gains of $2.5 million , net of tax, will be reclassified to earnings within the next twelve months . Substantially all currency cash flow hedges outstanding as of September 29, 2018 mature within twelve months . Non-Designated Foreign Currency Contracts The Company manages its exposure to changes in foreign currency on a consolidated basis to take advantage of offsetting transactions and balances. It uses foreign currency forward contracts as a part of its strategy to manage exposure related to foreign currency denominated monetary assets and liabilities. These foreign currency forward contracts are entered into for periods consistent with currency transaction exposures, generally one month. They are not designated as cash flow or fair value hedges under ASC 815. These forward contracts are marked-to-market with changes in fair value recorded to earnings. The Company had non-designated foreign currency hedge contracts under ASC 815 outstanding in the contract amount of $41.6 million as of September 29, 2018 and $36.3 million as of March 31, 2018 . Interest Rate Swaps On June 15, 2018, the Company entered into Credit Facilities which provided for a $350.0 million Term Loan and a $350.0 million Revolving Credit Facility. Under the terms of the Credit Facilities, interest is established using LIBOR plus 1.13% - 1.75% . As a result, the Company's earnings and cash flows are exposed to interest rate risk from changes to LIBOR. Part of the Company's interest rate risk management strategy includes the use of interest rate swaps to mitigate its exposure to changes in variable interest rates. The Company's objective in using interest rate swaps is to add stability to interest expense and to manage and reduce the risk inherent in interest rate fluctuations. In August 2018, the Company entered into two interest rate swap agreements (the "Swaps") to pay an average fixed rate of 2.80% on a total notional value of $241.9 million of debt. As a result of the interest rate swaps, 70% of the Term Loan exposed to interest rate risk from changes in LIBOR are fixed at a rate of 4.05% . The Swaps mature on June 15, 2023. The Company designated the Swaps as cash flow hedges of variable interest rate risk associated with $345.6 million of indebtedness. For fiscal 2019, $0.3 million of gains were recorded in accumulated other comprehensive loss to recognize the effective portion of the fair value of the Swaps that qualify as cash flow hedges. Fair Value of Derivative Instruments The following table presents the effect of the Company's derivative instruments designated as cash flow hedges and those not designated as hedging instruments under ASC 815 in its consolidated statements of income and comprehensive income for the six months ended September 29, 2018 : (In thousands) Amount of Gain Amount of (Loss) Reclassified Location in Amount of Gain Excluded from Testing Location in Designated foreign currency hedge contracts, net of tax $ 2,452 $ (730 ) Net revenues, COGS and SG&A $ 938 Interest and other expense, net Non-designated foreign currency hedge contracts — — $ 1,176 Interest and other expense, net Designated interest rate swaps, net of tax $ 306 $ — Interest and other expense, net $ — The Company did not have fair value hedges or net investment hedges outstanding as of September 29, 2018 or March 31, 2018 . As of September 29, 2018 , no deferred tax assets were recognized for designated foreign currency hedges. ASC 815 requires all derivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. The Company determines the fair value of its derivative instruments using the framework prescribed by ASC 820, Fair Value Measurements and Disclosures , by considering the estimated amount it would receive or pay to sell or transfer these instruments at the reporting date and by taking into account current interest rates, currency exchange rates, current interest rate curves, interest rate volatilities, the creditworthiness of the counterparty for assets, and its creditworthiness for liabilities. In certain instances, the Company may utilize financial models to measure fair value. Generally, it uses inputs that include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; other observable inputs for the asset or liability; and inputs derived principally from, or corroborated by, observable market data by correlation or other means. As of September 29, 2018 , the Company has classified its derivative assets and liabilities within Level 2 of the fair value hierarchy prescribed by ASC 815, as discussed below, because these observable inputs are available for substantially the full term of its derivative instruments. The following tables present the fair value of the Company's derivative instruments as they appear in its consolidated balance sheets as of September 29, 2018 and March 31, 2018 : (In thousands) Location in As of As of September 29, 2018 March 31, 2018 Derivative Assets: Designated foreign currency hedge contracts Other current assets $ 2,407 $ 780 Non-designated foreign currency hedge contracts Other current assets 213 324 Designated interest rate swaps Other current assets 306 — $ 2,926 $ 1,104 Derivative Liabilities: Designated foreign currency hedge contracts Other current liabilities $ 133 $ 1,445 Non-designated foreign currency hedge contracts Other current liabilities 84 138 $ 217 $ 1,583 Other Fair Value Measurements Fair value is defined as the exit price that would be received from the sale of an asset or paid to transfer a liability, using assumptions that market participants would use in pricing an asset or liability. The fair value guidance establishes the following three-level hierarchy used for measuring fair value: • Level 1 — Inputs to the valuation methodology are quoted market prices for identical assets or liabilities. • Level 2 — Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs. • Level 3 — Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk. The Company's money market funds carried at fair value are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. Fair Value Measured on a Recurring Basis Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of September 29, 2018 and March 31, 2018 . As of September 29, 2018 (In thousands) Level 1 Level 2 Total Assets Money market funds $ 70,961 $ — $ 70,961 Designated foreign currency hedge contracts — 2,407 2,407 Non-designated foreign currency hedge contracts — 213 213 Designated interest rate swaps — 306 306 $ 70,961 $ 2,926 $ 73,887 Liabilities Designated foreign currency hedge contracts $ — $ 133 $ 133 Non-designated foreign currency hedge contracts — 84 84 $ — $ 217 $ 217 As of March 31, 2018 Level 1 Level 2 Total Assets Money market funds $ 75,450 $ — $ 75,450 Designated foreign currency hedge contracts — 780 780 Non-designated foreign currency hedge contracts — 324 324 $ 75,450 $ 1,104 $ 76,554 Liabilities Designated foreign currency hedge contracts $ — $ 1,445 $ 1,445 Non-designated foreign currency hedge contracts — 138 138 $ — $ 1,583 $ 1,583 Other Fair Value Disclosures The Term Loan (which is carried at amortized cost), accounts receivable and accounts payable approximate fair value.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Sep. 29, 2018
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES The Company is a party to various legal proceedings and claims arising out of the ordinary course of its business. The Company believes that except for those matters described below, there are no other proceedings or claims pending against it the ultimate resolution of which could have a material adverse effect on the financial condition or results of operations. At each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies, for all matters. Legal costs are expensed as incurred. Litigation and Related Matters Product Recall In March 2018, the Company issued a voluntary recall of specific lots of its Acrodose Plus and PL Systems sold to its Blood Center customers in the U.S. The recall resulted from reports of low pH readings for platelets stored in the CLX HP bag and, in some instances, an accompanying yellow discoloration of the storage bag. For a period of nine weeks, the Company was unable to provide its customers with its Acrodose Plus and PL Systems. As a result of the recall, Blood Center customers may have discarded collected platelets and incurred other damages. As of September 29, 2018 , the Company has recorded cumulative charges of $2.0 million associated with this recall which consists of $1.3 million of charges associated with customer returns and inventory reserves and $0.7 million of charges associated with customer claims. The Company may record incremental charges for customer claims in future periods associated with this recall.

SEGMENT AND ENTERPRISE-WIDE INF

SEGMENT AND ENTERPRISE-WIDE INFORMATION	6 Months Ended
	Sep. 29, 2018
Segment Reporting [Abstract]
SEGMENT AND ENTERPRISE-WIDE INFORMATION	SEGMENT AND ENTERPRISE-WIDE INFORMATION The Company determines its reportable segments by first identifying its operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. The Company's operating segments are based primarily on geography. North America Plasma is a separate operating segment with dedicated segment management due the size and scale of the Plasma business unit. It aggregates components within an operating segment that have similar economic characteristics. The Company’s reportable segments are as follows: • Japan • EMEA • North America Plasma • All Other The Company has aggregated the Americas Blood Center and Hospital and Asia - Pacific operating segments into the All Other reportable segment based upon their similar operational and economic characteristics, including similarity of operating margin. Management measures and evaluates the operating segments based on operating income. Management excludes certain corporate expenses from segment operating income. In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment operating income because management evaluates the operating results of the segments excluding such items. These items include restructuring and turnaround costs, deal amortization, asset impairments, accelerated depreciation and certain legal charges. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow. Management measures and evaluates the Company's net revenues and operating income using internally derived standard currency exchange rates that remain constant from year to year; therefore, segment information is presented on this basis. During the first quarter of fiscal 2019, management reorganized its operating segments such that certain immaterial components of EMEA are now reported as components of All Other. Accordingly, the prior year numbers have been updated to reflect this reclassification as well as other changes within the cost reporting structure that occurred in the first quarter of fiscal 2019. These changes did not have an impact on its ability to aggregate Americas Blood Center and Hospital with Asia - Pacific. Selected information by business segment is presented below: Three Months Ended Six Months Ended (In thousands) September 29, September 30, September 29, September 30, Net revenues Japan $ 17,343 $ 17,164 $ 33,947 $ 32,396 EMEA 40,051 41,428 81,339 81,867 North America Plasma 99,655 85,051 191,229 162,587 All Other 85,482 82,551 165,294 163,294 Net revenues before foreign exchange impact 242,531 226,194 471,809 440,144 Effect of exchange rates (950 ) (817 ) (881 ) (3,816 ) Net revenues $ 241,581 $ 225,377 $ 470,928 $ 436,328 Three Months Ended Six Months Ended (In thousands) September 29, September 30, September 29, September 30, Segment operating income Japan $ 9,366 $ 8,656 $ 17,633 $ 16,123 EMEA 11,459 10,026 23,499 20,524 North America Plasma 41,468 34,692 80,064 61,892 All Other 36,229 32,529 69,270 63,199 Segment operating income 98,522 85,903 190,466 161,738 Corporate operating expenses (62,244 ) (50,456 ) (116,517 ) (98,505 ) Effect of exchange rates 2,594 1,102 5,649 (1,099 ) Restructuring and turnaround costs (2,118 ) (5,787 ) (5,467 ) (8,270 ) Deal amortization (6,236 ) (6,504 ) (12,536 ) (12,995 ) Asset impairments — — (21,170 ) — Accelerated depreciation (4,442 ) — (8,381 ) — Legal charges — — (675 ) — Operating income $ 26,076 $ 24,258 $ 31,369 $ 40,869 The Company's products are organized into three categories for purposes of evaluating their growth potential: Plasma, Blood Center and Hospital. Management reviews revenue trends based on these business units. Net revenues by business unit are as follows: Three Months Ended Six Months Ended (In thousands) September 29, September 30, September 29, September 30, Plasma $ 124,352 $ 109,771 $ 241,255 $ 211,278 Blood Center 68,243 71,710 132,726 137,275 Hospital 48,986 43,896 96,947 87,775 Net revenues $ 241,581 $ 225,377 $ 470,928 $ 436,328 Net revenues generated in the Company's principle operating regions on a reported basis are as follows: Three Months Ended Six Months Ended (In thousands) September 29, September 30, September 29, September 30, United States $ 152,926 $ 138,779 $ 295,066 $ 269,831 Japan 17,172 16,732 34,561 31,648 Europe 39,096 39,133 78,098 76,355 Asia 30,575 28,831 59,970 54,771 Other 1,812 1,902 3,233 3,723 Net revenues $ 241,581 $ 225,377 $ 470,928 $ 436,328

ACCUMULATED OTHER COMPREHENSIVE

ACCUMULATED OTHER COMPREHENSIVE LOSS	6 Months Ended
	Sep. 29, 2018
Stockholders' Equity Note [Abstract]
ACCUMULATED OTHER COMPREHENSIVE LOSS	ACCUMULATED OTHER COMPREHENSIVE LOSS The components of Accumulated Other Comprehensive Loss are as follows: (In thousands) Foreign Currency Defined Benefit Plans Net Unrealized Gain/Loss on Derivatives Total Balance as of March 31, 2018 $ (16,405 ) $ (323 ) $ (2,263 ) $ (18,991 ) Other comprehensive income (loss) before reclassifications (1) (8,530 ) — 2,758 (5,772 ) Amounts reclassified from Accumulated Other Comprehensive Loss (1) — — 730 730 Net current period other comprehensive income (loss) (8,530 ) — 3,488 (5,042 ) Balance as of September 29, 2018 $ (24,935 ) $ (323 ) $ 1,225 $ (24,033 ) (1) Presented net of income taxes, the amounts of which are insignificant.

RESTRUCTURING (Tables)

RESTRUCTURING (Tables)	6 Months Ended
	Sep. 29, 2018
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Reserve by Type of Cost	The following table summarizes the activity for restructuring reserves related to the 2018 Program and the 2017 Program for the six months ended September 29, 2018 , substantially all of which relates to employee severance and other employee costs: (In thousands) 2018 Program 2017 Program Total Balance at March 31, 2018 $ 27,129 $ 1,406 $ 28,535 Costs incurred, net of reversals (382 ) 57 (325 ) Payments (12,159 ) (984 ) (13,143 ) Non-cash adjustments (96 ) — (96 ) Balance at September 29, 2018 $ 14,492 $ 479 $ 14,971
Schedule of Restructuring and Related Costs	The tables below present restructuring and turnaround costs by reportable segment: Restructuring costs Three Months Ended Six Months Ended (In thousands) September 29, 2018 September 30, 2017 September 29, 2018 September 30, 2017 Japan $ 91 $ 2 $ 102 $ 111 EMEA (5 ) 15 119 25 North America Plasma — — (40 ) — All Other (119 ) 134 (506 ) 1,071 Total $ (33 ) $ 151 $ (325 ) $ 1,207 Turnaround costs Three Months Ended Six Months Ended (In thousands) September 29, 2018 September 30, 2017 September 29, 2018 September 30, 2017 Japan $ — $ — $ — $ — EMEA — 20 28 26 North America Plasma 31 197 41 349 All Other 2,120 5,419 5,723 6,688 Total $ 2,151 $ 5,636 $ 5,792 $ 7,063 Total restructuring and turnaround costs $ 2,118 $ 5,787 $ 5,467 $ 8,270

EARNINGS PER SHARE ("EPS") (Tab

EARNINGS PER SHARE ("EPS") (Tables)	6 Months Ended
	Sep. 29, 2018
Earnings Per Share [Abstract]
Schedule of Earnings Per Share Reconciliation	The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations. Three Months Ended Six Months Ended (In thousands, except per share amounts) September 29, September 30, September 29, September 30, Basic EPS Net income $ 18,726 $ 20,102 $ 15,907 $ 40,239 Weighted average shares 51,605 52,619 51,862 52,531 Basic income per share $ 0.36 $ 0.38 $ 0.31 $ 0.77 Diluted EPS Net income $ 18,726 $ 20,102 $ 15,907 $ 40,239 Basic weighted average shares 51,605 52,619 51,862 52,531 Net effect of common stock equivalents 1,533 362 1,503 365 Diluted weighted average shares 53,138 52,981 53,365 52,896 Diluted income per share $ 0.35 $ 0.38 $ 0.30 $ 0.76

INVENTORIES (Tables)

INVENTORIES (Tables)	6 Months Ended
	Sep. 29, 2018
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories are stated at the lower of cost or market and include the cost of material, labor and manufacturing overhead. Cost is determined using the first-in, first-out method. (In thousands) September 29, March 31, 2018 (1) Raw materials $ 51,028 $ 52,997 Work-in-process 13,075 10,774 Finished goods 99,481 97,028 Total inventories $ 163,584 $ 160,799 (1) The Company corrected the classification of inventory as of March 31, 2018. This correction did not change total inventories and did not have a financial statement impact.

PRODUCT WARRANTIES (Tables)

PRODUCT WARRANTIES (Tables)	6 Months Ended
	Sep. 29, 2018
Product Warranties Disclosures [Abstract]
Schedule of Product Warranty Liability	The Company estimates its potential warranty expense based on its historical warranty experience and periodically assesses the adequacy of its warranty accrual, making adjustments as necessary. Six Months Ended (In thousands) September 29, September 30, Warranty accrual as of the beginning of the period $ 316 $ 176 Warranty provision 333 796 Warranty spending (392 ) (537 ) Warranty accrual as of the end of the period $ 257 $ 435

DERIVATIVES AND FAIR VALUE ME_2

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Tables)	6 Months Ended
	Sep. 29, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments	The following table presents the effect of the Company's derivative instruments designated as cash flow hedges and those not designated as hedging instruments under ASC 815 in its consolidated statements of income and comprehensive income for the six months ended September 29, 2018 : (In thousands) Amount of Gain Amount of (Loss) Reclassified Location in Amount of Gain Excluded from Testing Location in Designated foreign currency hedge contracts, net of tax $ 2,452 $ (730 ) Net revenues, COGS and SG&A $ 938 Interest and other expense, net Non-designated foreign currency hedge contracts — — $ 1,176 Interest and other expense, net Designated interest rate swaps, net of tax $ 306 $ — Interest and other expense, net $ —
Schedule of Fair Value of Derivative Instruments as They Appear in Consolidated Balance Sheets	The following tables present the fair value of the Company's derivative instruments as they appear in its consolidated balance sheets as of September 29, 2018 and March 31, 2018 : (In thousands) Location in As of As of September 29, 2018 March 31, 2018 Derivative Assets: Designated foreign currency hedge contracts Other current assets $ 2,407 $ 780 Non-designated foreign currency hedge contracts Other current assets 213 324 Designated interest rate swaps Other current assets 306 — $ 2,926 $ 1,104 Derivative Liabilities: Designated foreign currency hedge contracts Other current liabilities $ 133 $ 1,445 Non-designated foreign currency hedge contracts Other current liabilities 84 138 $ 217 $ 1,583
Schedule of Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis	Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of September 29, 2018 and March 31, 2018 . As of September 29, 2018 (In thousands) Level 1 Level 2 Total Assets Money market funds $ 70,961 $ — $ 70,961 Designated foreign currency hedge contracts — 2,407 2,407 Non-designated foreign currency hedge contracts — 213 213 Designated interest rate swaps — 306 306 $ 70,961 $ 2,926 $ 73,887 Liabilities Designated foreign currency hedge contracts $ — $ 133 $ 133 Non-designated foreign currency hedge contracts — 84 84 $ — $ 217 $ 217 As of March 31, 2018 Level 1 Level 2 Total Assets Money market funds $ 75,450 $ — $ 75,450 Designated foreign currency hedge contracts — 780 780 Non-designated foreign currency hedge contracts — 324 324 $ 75,450 $ 1,104 $ 76,554 Liabilities Designated foreign currency hedge contracts $ — $ 1,445 $ 1,445 Non-designated foreign currency hedge contracts — 138 138 $ — $ 1,583 $ 1,583

SEGMENT AND ENTERPRISE-WIDE I_2

SEGMENT AND ENTERPRISE-WIDE INFORMATION (Tables)	6 Months Ended
	Sep. 29, 2018
Segment Reporting [Abstract]
Selected Information by Business Segment	Selected information by business segment is presented below: Three Months Ended Six Months Ended (In thousands) September 29, September 30, September 29, September 30, Net revenues Japan $ 17,343 $ 17,164 $ 33,947 $ 32,396 EMEA 40,051 41,428 81,339 81,867 North America Plasma 99,655 85,051 191,229 162,587 All Other 85,482 82,551 165,294 163,294 Net revenues before foreign exchange impact 242,531 226,194 471,809 440,144 Effect of exchange rates (950 ) (817 ) (881 ) (3,816 ) Net revenues $ 241,581 $ 225,377 $ 470,928 $ 436,328 Three Months Ended Six Months Ended (In thousands) September 29, September 30, September 29, September 30, Segment operating income Japan $ 9,366 $ 8,656 $ 17,633 $ 16,123 EMEA 11,459 10,026 23,499 20,524 North America Plasma 41,468 34,692 80,064 61,892 All Other 36,229 32,529 69,270 63,199 Segment operating income 98,522 85,903 190,466 161,738 Corporate operating expenses (62,244 ) (50,456 ) (116,517 ) (98,505 ) Effect of exchange rates 2,594 1,102 5,649 (1,099 ) Restructuring and turnaround costs (2,118 ) (5,787 ) (5,467 ) (8,270 ) Deal amortization (6,236 ) (6,504 ) (12,536 ) (12,995 ) Asset impairments — — (21,170 ) — Accelerated depreciation (4,442 ) — (8,381 ) — Legal charges — — (675 ) — Operating income $ 26,076 $ 24,258 $ 31,369 $ 40,869
Schedule of Revenues by Product Line and Geographic Regions	Net revenues by business unit are as follows: Three Months Ended Six Months Ended (In thousands) September 29, September 30, September 29, September 30, Plasma $ 124,352 $ 109,771 $ 241,255 $ 211,278 Blood Center 68,243 71,710 132,726 137,275 Hospital 48,986 43,896 96,947 87,775 Net revenues $ 241,581 $ 225,377 $ 470,928 $ 436,328 Net revenues generated in the Company's principle operating regions on a reported basis are as follows: Three Months Ended Six Months Ended (In thousands) September 29, September 30, September 29, September 30, United States $ 152,926 $ 138,779 $ 295,066 $ 269,831 Japan 17,172 16,732 34,561 31,648 Europe 39,096 39,133 78,098 76,355 Asia 30,575 28,831 59,970 54,771 Other 1,812 1,902 3,233 3,723 Net revenues $ 241,581 $ 225,377 $ 470,928 $ 436,328

ACCUMULATED OTHER COMPREHENSI_2

ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)	6 Months Ended
	Sep. 29, 2018
Stockholders' Equity Note [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	The components of Accumulated Other Comprehensive Loss are as follows: (In thousands) Foreign Currency Defined Benefit Plans Net Unrealized Gain/Loss on Derivatives Total Balance as of March 31, 2018 $ (16,405 ) $ (323 ) $ (2,263 ) $ (18,991 ) Other comprehensive income (loss) before reclassifications (1) (8,530 ) — 2,758 (5,772 ) Amounts reclassified from Accumulated Other Comprehensive Loss (1) — — 730 730 Net current period other comprehensive income (loss) (8,530 ) — 3,488 (5,042 ) Balance as of September 29, 2018 $ (24,935 ) $ (323 ) $ 1,225 $ (24,033 ) (1) Presented net of income taxes, the amounts of which are insignificant.

RECENT ACCOUNTING PRONOUNCEME_2

RECENT ACCOUNTING PRONOUNCEMENTS (Narrative) (Details) - ASU 2014-09 - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Sep. 29, 2018	Sep. 30, 2017	Sep. 29, 2018	Sep. 30, 2017	Apr. 01, 2018
Revenue | Software Contracts
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Concentration percentage	7.90%	8.50%	8.00%	8.40%
Difference between Revenue Guidance in Effect before and after Topic 606
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Increase to retained earnings					$ 1.5

RESTRUCTURING (Narrative) (Deta

RESTRUCTURING (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		18 Months Ended
	Sep. 29, 2018	Sep. 30, 2017	Sep. 29, 2018	Sep. 30, 2017	Sep. 29, 2018	Mar. 31, 2018
Restructuring Cost and Reserve [Line Items]
Restructuring and turnaround costs	$ 2,118	$ 5,787	$ 5,467	$ 8,270
Restructuring liability	14,971		14,971		$ 14,971	$ 28,535
Restructuring liability payable in next twelve months	13,600		13,600		13,600
Restructuring costs	(33)	151	(325)	1,207
Turnaround costs	2,151	5,636	5,792	7,063
2018 Program
Restructuring Cost and Reserve [Line Items]
Restructuring and turnaround costs	1,900		5,300		41,900
Restructuring liability	14,492		14,492		14,492	27,129
Restructuring costs			(382)
2018 Program | Minimum
Restructuring Cost and Reserve [Line Items]
Expected cost						50,000
2018 Program | Minimum | Employee Severance
Restructuring Cost and Reserve [Line Items]
Expected cost						35,000
2018 Program | Maximum
Restructuring Cost and Reserve [Line Items]
Expected cost						60,000
2018 Program | Maximum | Employee Severance
Restructuring Cost and Reserve [Line Items]
Expected cost						40,000
2017 Program
Restructuring Cost and Reserve [Line Items]
Restructuring and turnaround costs		$ 5,200		$ 7,700
Restructuring liability	$ 479		479		$ 479	$ 1,406
Restructuring costs			$ 57

RESTRUCTURING (Schedule of Rest

RESTRUCTURING (Schedule of Restructuring Reserve by Type of Cost) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 29, 2018	Sep. 30, 2017	Sep. 29, 2018	Sep. 30, 2017
Restructuring Reserve [Roll Forward]
Balance at March 31, 2018			$ 28,535
Costs incurred, net of reversals	$ (33)	$ 151	(325)	$ 1,207
Payments			(13,143)
Non-cash adjustments			(96)
Balance at September 29, 2018	14,971		14,971
2018 Program
Restructuring Reserve [Roll Forward]
Balance at March 31, 2018			27,129
Costs incurred, net of reversals			(382)
Payments			(12,159)
Non-cash adjustments			(96)
Balance at September 29, 2018	14,492		14,492
2017 Program
Restructuring Reserve [Roll Forward]
Balance at March 31, 2018			1,406
Costs incurred, net of reversals			57
Payments			(984)
Non-cash adjustments			0
Balance at September 29, 2018	$ 479		$ 479

RESTRUCTURING (Schedule of Re_2

RESTRUCTURING (Schedule of Restructuring and Related Costs) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 29, 2018	Sep. 30, 2017	Sep. 29, 2018	Sep. 30, 2017
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ (33)	$ 151	$ (325)	$ 1,207
Turnaround costs	2,151	5,636	5,792	7,063
Total restructuring and turnaround costs	2,118	5,787	5,467	8,270
Japan
Restructuring Cost and Reserve [Line Items]
Restructuring costs	91	2	102	111
Turnaround costs	0	0	0	0
EMEA
Restructuring Cost and Reserve [Line Items]
Restructuring costs	(5)	15	119	25
Turnaround costs	0	20	28	26
North America Plasma
Restructuring Cost and Reserve [Line Items]
Restructuring costs	0	0	(40)	0
Turnaround costs	31	197	41	349
All Other
Restructuring Cost and Reserve [Line Items]
Restructuring costs	(119)	134	(506)	1,071
Turnaround costs	$ 2,120	$ 5,419	$ 5,723	$ 6,688

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 29, 2018	Sep. 30, 2017	Sep. 29, 2018	Sep. 30, 2017
Income Tax Disclosure [Abstract]
Reported tax rate	18.70%		39.60%
Discrete tax benefit	$ 2,600
Impairment of assets			$ 21,170	$ 0
Provision (benefit) for income taxes	$ 4,311	$ 2,759	$ 10,445	$ 5,874

EARNINGS PER SHARE ("EPS") (Sch

EARNINGS PER SHARE ("EPS") (Schedule of Earnings Per Share Reconciliation) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 29, 2018	Sep. 30, 2017	Sep. 29, 2018	Sep. 30, 2017
Basic EPS
Net income	$ 18,726	$ 20,102	$ 15,907	$ 40,239
Basic weighted average shares (in shares)	51,605	52,619	51,862	52,531
Basic income per share (in dollars per share)	$ 0.36	$ 0.38	$ 0.31	$ 0.77
Diluted EPS
Net income	$ 18,726	$ 20,102	$ 15,907	$ 40,239
Basic weighted average shares (in shares)	51,605	52,619	51,862	52,531
Net effect of common stock equivalents (in shares)	1,533	362	1,503	365
Diluted weighted average shares (in shares)	53,138	52,981	53,365	52,896
Diluted income per share (in dollars per share)	$ 0.35	$ 0.38	$ 0.30	$ 0.76
Anti-dilutive shares excluded (in shares)	200	900	100	800

EARNINGS PER SHARE ("EPS") (Sha

EARNINGS PER SHARE ("EPS") (Share Repurchase Plan) (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended
	Aug. 31, 2018	May 31, 2018	Aug. 07, 2018	Feb. 06, 2018
ASR with Citibank
Accelerated Share Repurchases [Line Items]
Shares repurchased	$ 80	$ 100
Shares repurchased (in shares)	900,000	1,400,000
Repurchase price (in dollars per share)	$ 93.83	$ 72.51
Share Repurchase Plan
Accelerated Share Repurchases [Line Items]
Share repurchase plan, authorized amount				260,000,000
Remaining authorized amount			$ 80

REVENUE (Details)

REVENUE (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Sep. 29, 2018	Sep. 29, 2018	Apr. 01, 2018
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Performance obligation amount	$ 26.2	$ 26.2
Performance obligation percent	57.00%	57.00%
Expected timing of satisfaction	12 months	12 months
Contract assets	$ 5.2	$ 5.2	$ 2.7
Contract liabilities	16.4	16.4	16.6
Revenue recognized	$ 4.1	$ 11.5
Optional exemption term	1 year	1 year
ASU 2014-09 | Difference between Revenue Guidance in Effect before and after Topic 606
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Increase to retained earnings			$ 1.5

INVENTORIES (Schedule of Invent

INVENTORIES (Schedule of Inventories) (Details) - USD ($) $ in Thousands	Sep. 29, 2018	Mar. 31, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 51,028	$ 52,997
Work-in-process	13,075	10,774
Finished goods	99,481	97,028
Inventories, net	$ 163,584	$ 160,799

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended		6 Months Ended	12 Months Ended
	May 31, 2018	Sep. 29, 2018	Jun. 30, 2018	Sep. 29, 2018	Mar. 31, 2012
HDC Line
Property, Plant and Equipment [Line Items]
Payments to acquire productive assets	$ 9				$ 15
Carrying value		$ 19.8		$ 19.8
Impairment charges			$ 19.8
Non-core and Underperforming Assets
Property, Plant and Equipment [Line Items]
Impairment charges			$ 1.4
PCS2 Devices
Property, Plant and Equipment [Line Items]
Depreciation		$ 4.4		$ 8.4

CAPITALIZATION OF SOFTWARE DE_2

CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS (Narrative) (Details) - USD ($) $ in Millions	6 Months Ended
	Sep. 29, 2018	Sep. 30, 2017	Mar. 31, 2018
Research and Development [Abstract]
Capitalized software development costs for ongoing initiatives	$ 1.5	$ 6.4
Software costs capitalized, net	73.3		$ 71.8
Total costs capitalized related to in process software development initiatives	8.6		$ 17.7
Capitalized software development costs placed into service	$ 10.6

PRODUCT WARRANTIES (Schedule of

PRODUCT WARRANTIES (Schedule of Product Warranty Liability) (Details) - USD ($) $ in Thousands	6 Months Ended
	Sep. 29, 2018	Sep. 30, 2017
Product Warranties Disclosures [Abstract]
General Warranty Period on Parts and Labor	1 year
Product Warranties [Roll Forward]
Warranty accrual as of the beginning of the period	$ 316	$ 176
Warranty provision	333	796
Warranty spending	(392)	(537)
Warranty accrual as of the end of the period	$ 257	$ 435

DEBT (Details)

DEBT (Details) - USD ($)	Jun. 15, 2018	Sep. 29, 2018
Credit Facilities
Debt Instrument [Line Items]
Extinguishment of debt	$ 253,700,000
Credit Facilities
Debt Instrument [Line Items]
Proceeds from debt	347,800,000
Principal repayments, fiscal 2019		$ 8,800,000
Principal repayments, fiscal 2020		17,500,000
Principal repayments, fiscal 2021		17,500,000
Principal repayments, fiscal 2022		17,500,000
Principal repayments, fiscal 2023		214,400,000
Principal repayments, thereafter		70,000,000
Term Loan
Debt Instrument [Line Items]
Face amount of debt	350,000,000
Debt outstanding		$ 345,600,000
Effective interest rate		3.50%
Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 350,000,000
Debt outstanding		$ 0
Revolving Credit Facility | LIBOR | Minimum
Debt Instrument [Line Items]
Interest rate	1.13%
Revolving Credit Facility | LIBOR | Maximum
Debt Instrument [Line Items]
Interest rate	1.75%
Uncommitted Operating Lines of Credit
Debt Instrument [Line Items]
Maximum borrowing capacity		24,500,000
Debt outstanding		$ 0

DERIVATIVES AND FAIR VALUE ME_3

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments) (Details) $ in Thousands	6 Months Ended
	Sep. 29, 2018USD ($)
Designated as Hedging Instrument | Cash Flow Hedging | Net revenues, COGS and SG&A
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in AOCI (Effective Portion)	$ 2,452
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion)	(730)
Designated as Hedging Instrument | Cash Flow Hedging | Interest and other expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount Excluded from Effectiveness Testing	938
Designated as Hedging Instrument | Interest Rate Swap
Derivative Instruments, Gain (Loss) [Line Items]
Amount Excluded from Effectiveness Testing	0
Designated as Hedging Instrument | Interest Rate Swap | Interest and other expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in AOCI (Effective Portion)	306
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion)	0
Not Designated as Hedging Instrument | Foreign Exchange Contract
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in AOCI (Effective Portion)	0
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion)	0
Not Designated as Hedging Instrument | Foreign Exchange Contract | Interest and other expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount Excluded from Effectiveness Testing	$ 1,176

DERIVATIVES AND FAIR VALUE ME_4

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedules of Derivatives) (Details) - USD ($) $ in Thousands	Sep. 29, 2018	Mar. 31, 2018
Designated as Hedging Instrument
Assets
Derivative Assets	$ 2,926	$ 1,104
Liabilities
Derivative Liabilities	217	1,583
Foreign Exchange Contract | Other Current Assets | Designated as Hedging Instrument
Assets
Derivative Assets		780
Foreign Exchange Contract | Other Current Assets | Not Designated as Hedging Instrument
Assets
Derivative Assets		324
Foreign Exchange Contract | Other Current Liabilities | Designated as Hedging Instrument
Liabilities
Derivative Liabilities		1,445
Foreign Exchange Contract | Other Current Liabilities | Not Designated as Hedging Instrument
Liabilities
Derivative Liabilities		138
Interest Rate Swap | Other Current Assets | Designated as Hedging Instrument
Assets
Derivative Assets		0
Fair Value, Measurements, Recurring [Member]
Assets
Money market funds	70,961	75,450
Assets fair value	73,887	76,554
Liabilities
Liabilities fair value	217	1,583
Fair Value, Measurements, Recurring [Member] | Level 1
Assets
Money market funds	70,961	75,450
Assets fair value	70,961	75,450
Liabilities
Liabilities fair value	0	0
Fair Value, Measurements, Recurring [Member] | Level 2
Assets
Money market funds	0	0
Assets fair value	2,926	1,104
Liabilities
Liabilities fair value	217	1,583
Fair Value, Measurements, Recurring [Member] | Designated as Hedging Instrument
Assets
Derivative Assets	2,407	780
Liabilities
Derivative Liabilities	133	1,445
Fair Value, Measurements, Recurring [Member] | Designated as Hedging Instrument | Level 1
Assets
Derivative Assets	0	0
Liabilities
Derivative Liabilities	0	0
Fair Value, Measurements, Recurring [Member] | Designated as Hedging Instrument | Level 2
Assets
Derivative Assets		780
Liabilities
Derivative Liabilities		1,445
Fair Value, Measurements, Recurring [Member] | Not Designated as Hedging Instrument
Assets
Derivative Assets	213	324
Liabilities
Derivative Liabilities	84	138
Fair Value, Measurements, Recurring [Member] | Not Designated as Hedging Instrument | Level 1
Assets
Derivative Assets	0	0
Liabilities
Derivative Liabilities	0	0
Fair Value, Measurements, Recurring [Member] | Not Designated as Hedging Instrument | Level 2
Assets
Derivative Assets		324
Liabilities
Derivative Liabilities		$ 138
Fair Value, Measurements, Recurring [Member] | Foreign Exchange Contract | Other Current Assets | Designated as Hedging Instrument | Level 2
Assets
Derivative Assets	2,407
Fair Value, Measurements, Recurring [Member] | Foreign Exchange Contract | Other Current Assets | Not Designated as Hedging Instrument | Level 2
Assets
Derivative Assets	213
Fair Value, Measurements, Recurring [Member] | Foreign Exchange Contract | Other Current Liabilities | Designated as Hedging Instrument | Level 2
Liabilities
Derivative Liabilities	133
Fair Value, Measurements, Recurring [Member] | Foreign Exchange Contract | Other Current Liabilities | Not Designated as Hedging Instrument | Level 2
Liabilities
Derivative Liabilities	84
Fair Value, Measurements, Recurring [Member] | Interest Rate Swap | Other Current Assets | Designated as Hedging Instrument
Assets
Derivative Assets	306
Fair Value, Measurements, Recurring [Member] | Interest Rate Swap | Other Current Assets | Designated as Hedging Instrument | Level 1
Assets
Derivative Assets	0
Fair Value, Measurements, Recurring [Member] | Interest Rate Swap | Other Current Assets | Designated as Hedging Instrument | Level 2
Assets
Derivative Assets	$ 306

DERIVATIVES AND FAIR VALUE ME_5

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Narrative) (Details)	Jun. 15, 2018USD ($)	Sep. 29, 2018USD ($)	Sep. 29, 2018USD ($)	Aug. 31, 2018USD ($)swap	Mar. 31, 2018USD ($)
Term Loan
Derivative [Line Items]
Face amount of debt	$ 350,000,000
Debt outstanding		$ 345,600,000	$ 345,600,000
Revolving Credit Facility
Derivative [Line Items]
Maximum borrowing capacity	$ 350,000,000
Debt outstanding		$ 0	$ 0
Revolving Credit Facility | LIBOR | Minimum
Derivative [Line Items]
Interest rate	1.13%
Revolving Credit Facility | LIBOR | Maximum
Derivative [Line Items]
Interest rate	1.75%
Foreign Exchange Contract
Derivative [Line Items]
Percentage of sales generated outside the US		36.70%	37.30%
Maturity period for foreign currency contracts			1 year
Cash Flow Hedging | Interest Rate Swap
Derivative [Line Items]
Number of instruments held | swap				2
Derivative fixed interest rate				2.80%
Notional amount				$ 241,900,000
Gains recorded in accumulated other comprehensive income			$ 300,000
Cash Flow Hedging | Interest Rate Swap | LIBOR
Derivative [Line Items]
Debt exposed to interest rate risk				70.00%
Derivative fixed interest rate				4.05%
Designated as Hedging Instrument | Foreign Exchange Contract
Derivative [Line Items]
Deferred income tax expense (benefit)		$ 0	0
Designated as Hedging Instrument | Foreign Exchange Contract
Derivative [Line Items]
Designated foreign currency hedge contracts outstanding		59,000,000	59,000,000		$ 86,000,000
Designated as Hedging Instrument | Cash Flow Hedging
Derivative [Line Items]
Gain (loss) to be reclassified within the next twelve months			2,500,000
Not Designated as Hedging Instrument | Foreign Exchange Contract
Derivative [Line Items]
Non-designated foreign currency hedge contracts outstanding		$ 41,600,000	$ 41,600,000		$ 36,300,000

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details) - Product Recall $ in Millions	6 Months Ended
	Sep. 29, 2018USD ($)
Loss Contingencies [Line Items]
Loss in period	$ 2
Customer Returns and Inventory Reserves
Loss Contingencies [Line Items]
Loss in period	1.3
Customer Claims
Loss Contingencies [Line Items]
Loss in period	$ 0.7

SEGMENT AND ENTERPRISE-WIDE I_3

SEGMENT AND ENTERPRISE-WIDE INFORMATION (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 29, 2018USD ($)	Sep. 30, 2017USD ($)	Sep. 29, 2018USD ($)unit	Sep. 30, 2017USD ($)
Segment Reporting [Abstract]
Number of business units | unit			3
Segment Reporting Information [Line Items]
Net revenues before foreign exchange impact	$ 242,531	$ 226,194	$ 471,809	$ 440,144
Effect of exchange rates	(950)	(817)	(881)	(3,816)
Net revenues	241,581	225,377	470,928	436,328
Effect of exchange rates	2,594	1,102	5,649	(1,099)
Restructuring and turnaround costs	(2,118)	(5,787)	(5,467)	(8,270)
Deal amortization	(6,236)	(6,504)	(12,536)	(12,995)
Asset impairments	0	0	(21,170)	0
Accelerated depreciation	0	0	(8,381)	0
Legal charges	(4,442)	0	(675)	0
Operating income	26,076	24,258	31,369	40,869
Plasma
Segment Reporting Information [Line Items]
Net revenues	124,352	109,771	241,255	211,278
Blood Center
Segment Reporting Information [Line Items]
Net revenues	68,243	71,710	132,726	137,275
Hospital
Segment Reporting Information [Line Items]
Net revenues	48,986	43,896	96,947	87,775
United States
Segment Reporting Information [Line Items]
Net revenues	152,926	138,779	295,066	269,831
Japan
Segment Reporting Information [Line Items]
Net revenues	17,172	16,732	34,561	31,648
Europe
Segment Reporting Information [Line Items]
Net revenues	39,096	39,133	78,098	76,355
Asia
Segment Reporting Information [Line Items]
Net revenues	30,575	28,831	59,970	54,771
Other
Segment Reporting Information [Line Items]
Net revenues	1,812	1,902	3,233	3,723
Japan
Segment Reporting Information [Line Items]
Net revenues before foreign exchange impact	17,343	17,164	33,947	32,396
EMEA
Segment Reporting Information [Line Items]
Net revenues before foreign exchange impact	40,051	41,428	81,339	81,867
North America Plasma
Segment Reporting Information [Line Items]
Net revenues before foreign exchange impact	99,655	85,051	191,229	162,587
All Other
Segment Reporting Information [Line Items]
Net revenues before foreign exchange impact	85,482	82,551	165,294	163,294
Operating Segments
Segment Reporting Information [Line Items]
Operating income	98,522	85,903	190,466	161,738
Operating Segments | Japan
Segment Reporting Information [Line Items]
Operating income	9,366	8,656	17,633	16,123
Operating Segments | EMEA
Segment Reporting Information [Line Items]
Operating income	11,459	10,026	23,499	20,524
Operating Segments | North America Plasma
Segment Reporting Information [Line Items]
Operating income	41,468	34,692	80,064	61,892
Operating Segments | All Other
Segment Reporting Information [Line Items]
Operating income	36,229	32,529	69,270	63,199
Corporate operating expenses
Segment Reporting Information [Line Items]
Corporate operating expenses	$ (62,244)	$ (50,456)	$ (116,517)	$ (98,505)

ACCUMULATED OTHER COMPREHENSI_3

ACCUMULATED OTHER COMPREHENSIVE LOSS (Details) $ in Thousands	6 Months Ended
	Sep. 29, 2018USD ($)
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance as of March 31, 2018	$ (18,991)
Other comprehensive income (loss) before reclassifications	(5,772)
Amounts reclassified from Accumulated Other Comprehensive Income (Loss)	730
Net current period other comprehensive income (loss)	(5,042)
Balance as of September 29, 2018	(24,033)
Foreign Currency
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance as of March 31, 2018	(16,405)
Other comprehensive income (loss) before reclassifications	(8,530)
Amounts reclassified from Accumulated Other Comprehensive Income (Loss)	0
Net current period other comprehensive income (loss)	(8,530)
Balance as of September 29, 2018	(24,935)
Defined Benefit Plans
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance as of March 31, 2018	(323)
Other comprehensive income (loss) before reclassifications	0
Amounts reclassified from Accumulated Other Comprehensive Income (Loss)	0
Net current period other comprehensive income (loss)	0
Balance as of September 29, 2018	(323)
Net Unrealized Gain/Loss on Derivatives
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance as of March 31, 2018	(2,263)
Other comprehensive income (loss) before reclassifications	2,758
Amounts reclassified from Accumulated Other Comprehensive Income (Loss)	730
Net current period other comprehensive income (loss)	3,488
Balance as of September 29, 2018	$ 1,225